Farallon Capital Management
http://www.faralloncapital.com/farallon/index.htmFarallon Capital Management is an investment firm than manages equity capital for institutions and high net worth individuals. The firm's institutional investors are primarily college endowments and foundations. Farallon primarily invests in businesses and securities that are undergoing change or will appreciate because of an expected event which includes mergers, restructurings, recapitalizations or other major changes. The firm seeks to build strong relationships with the management of companies in which it invests.
View Older Stories
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Mar 31
-
Form SCHEDULE 13G InflaRx N.V. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Tyra Biosciences, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Beta Bionics, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A GRAIL, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Tango Therapeutics, Inc. Filed by: Farallon Capital Partners, L.P.
-
InflaRx completes $150 million share offering at $2.00 per share
-
InflaRx prices $150 million stock offering at $2 per share
-
Sagimet prices $175 million stock offering at $6 per share
-
Maze Therapeutics prices $150 million stock offering at $23.50 per share
-
Form D/A Farallon Capital (AM)
-
Form D/A Farallon Capital Partner
-
Form D/A FARALLON CAPITAL OFFSHOR
-
Form D/A Farallon Capital Institu
-
Form SCHEDULE 13G Tyra Biosciences, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form SCHEDULE 13G/A Liquidia Corp Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Revolution Medicines, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Beta Bionics, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A GRAIL, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A ASSEMBLY BIOSCIENCES, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Savara Inc Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G/A Crinetics Pharmaceutical Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
-
Form SCHEDULE 13G Minerva Neurosciences, Filed by: Farallon Capital Partners, L.P.
-
Freenome to go public via SPAC merger with $240 million funding
-
Form SCHEDULE 13G GRAIL, Inc. Filed by: Farallon Capital Partners, L.P.
-
Form N-PX/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
-
Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
-
Form SCHEDULE 13G GRAIL, Inc. Filed by: Farallon Capital Partners, L.P.

